Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP 450 Inhibition and Anticoagulation Biomarker Alteration by Radix Puerariae Lobatae (Gegen)
NCT07823140Phase 1Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of kudzu root (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoints: Change in CYP1A2 phenotypic activity at 14 days, Change in CYP2B6 phenotypic activity at 14 days and 7 more. Started Aug 2022; status: completed.
02
Drugs
kudzu root
Beyond the preview
Go deeper on NCT07823140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07823140.